BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 06, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lovenox enoxaparin: Phase III data

In the open-label, international Phase III ATOLL trial in 910 patients, 0.5 mg/kg IV Lovenox administered prior to percutaneous coronary intervention (PCI) non-significantly reduced the composite primary endpoint of death, complication from MI, procedure failure or major bleeding...

Read the full 170 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >